CHADDS FORD, Pa., March 31, 2005 – Today at the 24th Annual Scientific Meeting of the American Pain Society, Endo Pharmaceuticals Inc. released new clinical trial data which found patients receiving ...

The pharmacokinetics, safety, and tolerability of four topical lidocaine patches 5% continuously applied for 72 hours and changed every 12 or 24 hours were examined. In this randomized, prospective, ...

PHILADELPHIA (Legal Newsline) – Endo Health Solutions Inc. and its subsidiary, Endo Pharmaceuticals, have agreed to a $171.9 million settlement with the federal government to resolve off-label ...

Amneal has received Food and Drug Administration approval for its lidocaine patch 5%. The product is a generic of Lidoderm Patch 5%. “We are pleased to announce the approval for the Lidocaine Patch, 5 ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from ...

opioids In a meta-analysis, researchers evaluated whether a lidocaine patch is beneficial for postoperative pain as an option for multimodal analgesia. The use of lidocaine patches for postoperative ...

Says partners got para IV notification from Watson Labs Says to defend Lidoderm's intellectual property rights Shares down 3 pct pre-market Jan 19 (Reuters) - Endo Pharmaceuticals Holdings Inc said ...

A woman in pain holding her neck Intravenous, patch lidocaine might be effective in treating, preventing chronic pain. As many as 116 million adults experience chronic pain each year in the United ...

Lidocaine patches are a form of local anesthetic that people may use to treat areas of pain on their body. The medication in the patches has a numbing effect on the nerves that send pain signals to ...

SAN FRANCISCO (MarketWatch) -- Endo Pharmaceutical Holdings Inc. after Tuesday's closing bell said that the Food and Drug Administration's Office of Generic Drugs has issued bioequivalence ...

Scilex Holding Company announced the publication of a study in Pain Medicine News revealing that patients treated with ZTlido® (lidocaine topical system 1.8%) showed a greater reduction in opioid use ...